Sandostatin Injection is available as: sterile 1-mL ampuls in 3 strengths, containing 50, mcg octreotide (as acetate), and sterile 5-mL multi-dose vials in 2. Sep 3, Octreotide Acetate (Sandostatin ®) – Intravenous (IV) Dilution. Octreotide (Sandostatin) is the longer acting synthetic analogue of the naturally In patients with cancer and inoperable bowel obstruction octreotide rapidly.
|Published (Last):||28 November 2009|
|PDF File Size:||17.5 Mb|
|ePub File Size:||15.95 Mb|
|Price:||Free* [*Free Regsitration Required]|
Keep the vial in the outer carton in order to protect from light. Enter medicine name or company Start typing to retrieve search suggestions.
Dosing Sandostatin® LAR®
Symptomatic control and reduction of growth hormone GH and IGF-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. Contains less than 1 mmol 23 mg sodium per dose, i. Impaired renal function did not affect the total exposure AUC to octreotide administered as s. At least 5 days of treatment will be needed to judge the efficacy. Hepatobiliary disorders Acute pancreatitis, acute hepatitis without cholestasis, cholestatic hepatitis, cholestasis, jaundice, cholestatic jaundice.
Local Site Reactions In a week toxicity study in rats, predominantly in males, sarcomas were noted at the s. Somatostatin and analogues, ATC code: Disclaimer The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a octreotiee for clinical judgment.
Acromegaly Dosage may be initiated at 50 mcg t.
In addition, cholelithiasis induced pancreatitis has been reported for patients on long-term Octreotide s. Tabulated list of adverse reactions The following adverse drug reactions, listed in Table 1, have ovtreotide accumulated from clinical studies with octreotide: The elimination half-life after s.
It is therefore recommended to monitor glucose tolerance and antidiabetic treatment.
SANDOSTATIN Dosage & Rx Info | Uses, Side Effects – MPR
Use in patients with impaired renal function Impaired renal function did not affect the total exposure AUC to octreotide administered as s. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity see section 5. GH in patients with acromegaly.
Step 5 Remove cap from syringe and screw syringe onto vial adapter Slowly push plunger all the way down to transfer all the diluent solution in the vial. Gallbladder abnormalities may occur: Diarrhea due to chemotherapy: Shelf-life after first opening: Glucose metabolism Because of its inhibitory action on growth hormone, glucagon, and insulin, Sandostatin may affect glucose regulation.
Sandostatin LAR Depot [prescribing information].
Sandostatin is not compatible in Total Parenteral Nutrition TPN solutions because of the formation of a glycosyl octreotide conjugate which may decrease the efficacy of the product. Maintenance doses have to be adjusted individually. Acute pancreatitis, acute hepatitis without cholestasis, cholestatic hepatitis, cholestasis, jaundice, cholestatic jaundice.
Intravenous infusion Prior to administration the solution should be inspected visually for changes of colour or solid particles. Spontaneously reported adverse reactions, presented in Table 2, are reported voluntarily and it is not always possible to reliably establish frequency or a causal relationship to drug exposure. Sandostatin may be administered directly by subcutaneous s.
Dosing & Administration
Table 1 Adverse drug reactions reported in clinical studies Gastrointestinal disorders Very common: Under exceptional circumstances, higher doses may be required.
The earliest reduction was reported after 14 days of treatment. However, because Sandostatin can affect glucose homeostasis, it is recommended that physiological saline solutions be used rather than dextrose. Show table of contents Hide table of contents 1.
Treatment of TSH-secreting pituitary adenomas The treatment effects of Sandostatin were prospectively dosi in 21 patients and pooled with series of 37 published cases. Patients who are to self-administer the drug by s.
As a precautionary measure, it is preferable to avoid the use of Octreotide during pregnancy see section 4. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, Website: The product must octrotide used immediately and any unused drug-product must be discarded. During the treatment of GEP endocrine tumours, there may be rare instances of sudden escape from symptomatic control by Octreotide with rapid recurrence of severe symptoms.